Advertisement


Sara Khan, DO, on the Gender Gap in Receiving NIH Grants for Hematology Research

2023 ASH

Advertisement

Sara Khan, DO, of the University of South Florida Morsani College of Medicine and HCA Healthcare, discusses her findings showing that women received only 33% of grants from the National Institutes of Health from 2012 to 2022 in nonmalignant hematologic research. Although some agencies have made strides in this area, others continue to have a significant gap. Identifying these areas of gender disparity will enable targeted efforts to bridge this gap and advance gender equality (Abstract 5113).



Related Videos

Lymphoma

Bijal D. Shah, MD, on Previously Treated Mantle Cell Lymphoma: New Findings on Brexucabtagene Autoleucel and Pirtobrutinib

Bijal D. Shah, MD, of Moffitt Cancer Center and Research Institute, discusses a matching-adjusted indirect comparison of brexucabtagene autoleucel and pirtobrutinib in patients with relapsed or refractory mantle cell lymphoma who have been previously treated with a BTK inhibitor (Abstract 5136).

Lymphoma

Sarah C. Rutherford, MD, on Hodgkin Lymphoma: Nivolumab Plus AVD in Older Patients With Advanced-Stage Disease

Sarah C. Rutherford, MD, of Weill Cornell Medicine, discusses findings of the SWOG S1826 study, which showed nivolumab plus AVD (doxorubicin, vinblastine, and dacarbazine) improved progression-free and event-free survival and seemed to be better tolerated than brentuximab vedotin plus AVD in patients aged 60 and older with advanced-stage Hodgkin lymphoma (Abstract 181).

Lymphoma

Jonathon B. Cohen, MD, on Mantle Cell Lymphoma: New Data on Pirtobrutinib

Jonathon B. Cohen, MD, of Winship Cancer Institute, Emory University, discusses safety and efficacy findings from the phase I/II BRUIN study. The trial found that pirtobrutinib continues to demonstrate durable efficacy and a favorable safety profile in heavily pretreated patients with relapsed or refractory mantle cell lymphoma (Abstract 981).

Lymphoma

Mazyar Shadman, MD, MPH, on Large B-Cell Lymphoma: Autologous Transplantation vs CAR T-Cell Therapy

Mazyar Shadman, MD, MPH, of the University of Washington, discusses new data suggesting that in patients with relapsed large B-cell lymphoma who achieve a complete response, treatment with autologous transplantation may be associated with a lower relapse rate and improved progression-free survival compared with CAR T-cell therapy, including those with early treatment failure (Abstract 781).

Multiple Myeloma

Danai Dima, MD, on Multiple Myeloma: Update on Safety and Efficacy of Teclistamab

Danai Dima, MD, of the Taussig Cancer Institute, Cleveland Clinic, discusses teclistamab-cqyv, a B-cell maturation antigen approved in October 2022 for patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy. Dr. Dima and her team evaluated the real-world safety and efficacy of this agent and found encouraging evidence of efficacy in a real-world setting (Abstract 91).

Advertisement

Advertisement




Advertisement